FFA
RXRX icon

Farther Finance Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Farther Finance Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.4K Buy
13,741
+4,778
+53% +$15.9K ﹤0.01% 3240
2026
Q1 		$27.4K Buy
8,963
+1,551
+21% +$5.99K ﹤0.01% 3434
2025
Q4 		$30.3K Sell
7,412
-12,178
-62% -$60.3K ﹤0.01% 3145
2025
Q3 		$95.6K Buy
19,590
+5,388
+38% +$28.3K ﹤0.01% 2062
2025
Q2 		$71.9K Buy
14,202
+6,470
+84% +$31.8K ﹤0.01% 1939
2025
Q1 		$39.4K Sell
7,732
-25
-0.3% -$182 ﹤0.01% 2018
2024
Q4 		$52.4K Buy
7,757
+1,353
+21% +$9.1K ﹤0.01% 1640
2024
Q3 		$42.2K Buy
6,404
+4,091
+177% +$29.3K ﹤0.01% 1742
2024
Q2 		$17.3K Buy
2,313
+135
+6% +$1.18K ﹤0.01% 1831
2024
Q1 		$20.4K Buy
2,178
+2,136
+5,086% +$23.8K ﹤0.01% 1488
2023
Q4 		$414 Buy
+42
New +$299 ﹤0.01% 3030

Other funds holding RXRX

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return
PL
Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AWM
Accel Wealth Management Waverly, Iowa $444M AUM 31.14% 1-Year Est. Return
NWMG
National Wealth Management Group Cincinnati, Ohio $323M AUM 39.23% 1-Year Est. Return
WPC
Wedmont Private Capital West Chester, Pennsylvania $3.65B AUM 26.64% 1-Year Est. Return
IIA
Integral Investment Advisors Turlock, California $454M AUM 21.42% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

Farther Finance Advisors's RXRX Position: Q2 2026 in Review

Farther Finance Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 53% in Q2 2026, buying an estimated $15.9K and bringing the position to 13,741 shares worth $50.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3240.

Farther Finance Advisors first reported a position in RXRX in Q4 2023 and has held it in 11 quarters since. The position peaked at $95.6K in Q3 2025. 24 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Farther Finance Advisors held 13,741 shares of Recursion Pharmaceuticals worth $50.4K as of Q2 2026.
  • Farther Finance Advisors bought 4,778 Recursion Pharmaceuticals shares in Q2 2026, an estimated $15.9K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #3240 holding.
  • Farther Finance Advisors first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Farther Finance Advisors's Recursion Pharmaceuticals position peaked at $95.6K in Q3 2025.
  • 24 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.